Imperial College London
Portrait Picture

DrVictoriaSalem

Faculty of Engineering, Department of Bioengineering

Clinical Senior Lecturer in Diabetes and Endocrinology
 
 
 
//

Contact

 

v.salem

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sam:2011:2011/432607,
author = {Sam, AH and Salem, V and Ghatei, MA},
doi = {2011/432607},
journal = {J Obes},
title = {Rimonabant: From RIO to Ban.},
url = {http://dx.doi.org/10.1155/2011/432607},
volume = {2011},
year = {2011}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects-notably severe mood disorders. This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.
AU  - Sam,AH
AU  - Salem,V
AU  - Ghatei,MA
DO  - 2011/432607
PY  - 2011///
TI  - Rimonabant: From RIO to Ban.
T2  - J Obes
UR  - http://dx.doi.org/10.1155/2011/432607
UR  - https://www.ncbi.nlm.nih.gov/pubmed/21773005
VL  - 2011
ER  -
Download